Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 12, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Factor XI Clear all

Conditions: Atrial Fibrillation (AF)
Interventions: REGN7508, Apixaban, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 15,364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Dothan, Alabama • Newport Beach, California • Pasadena, California + 5 more

Conditions: End Stage Renal Disease Requiring Hemodialysis
Interventions: Fesomersen sodium (BAY2976217), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more

Conditions: Stroke
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Thrombosis, Factor XI, Renal Impairment, ESRD (End-Stage Renal Disease)
Interventions: BMS-986177; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Symptomatic Venous Thromboembolism (VTE)
Interventions: REGN7508, Acetylsalicylic Acid (ASA), Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: La Mesa, California • Rancho Mirage, California • Lone Tree, Colorado + 21 more

Conditions: Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery
Interventions: Hemoleven; Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: 6 Months and older
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Peripheral Artery Disease (PAD)
Interventions: REGN7508, REGN9933, Placebo, Rivaroxaban; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 7,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 14 more

Conditions: Post-thrombotic Syndrome, Deep Vein Thrombosis Leg
Interventions: Rosuvastatin; Drug
Lead sponsor: Khanh Nguyen; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Venous Thromboembolism (VTE)
Interventions: REGN7508, Apixaban; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Hialeah, Florida • New York, New York • El Paso, Texas

Conditions: Venous Thromboembolism
Interventions: REGN9933, REGN7508, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Venous Thromboembolism (VTE)
Interventions: REGN7508, Apixaban, Enoxaparin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Sheffield, Alabama • Riverside, California • Englewood, Colorado + 16 more

Conditions: Atrial Fibrillation (AF), Stroke
Interventions: Abelacimab, Rivaroxaban; Biological · Drug
Lead sponsor: Anthos Therapeutics, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 1,287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 28
States / cities: Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more

Conditions: Atrial Fibrillation (AF)
Interventions: REGN7508, REGN9933, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Dothan, Alabama • Fremont, California • Huntington Beach, California + 15 more

Conditions: End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions: MK-2060, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 77
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Search by objective public record fields.

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

Factor XI Levels in Acute Ischemic Stroke

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)